Clinical trial · Interventional
Trial of IV Injection of CV787 in Hormone Refractory Metastatic Prostate Cancer
A Phase I/II Dose Finding Trial of the Intravenous Injection of CV787, a Prostate-Specific Antigen Cytolytic Adenovirus, in Patients With Hormone Refractory Metastatic Prostate Cancer
NCT00116155CI-TRIAL-00000101completedPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a multi-center, open-label, dose finding study of CV787 adenovirus in patients with hormone refractory metastatic prostate cancer. Patients will receive treatment intravenously at one of up to nine dose levels, each containing three to six patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| CV787 (CG7870) | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- To determine the safety, tolerability, and the maximum tolerated dose of CG7870 when administered intravenously to patients with progressive metastatic hormone refractory prostate cancer
Secondary outcomes (4)
- measure
- To evaluate prostate-specific antigen (PSA) response rates, duration of response, and time to disease progression
- measure
- To evaluate other clinical efficacy responses observed
- measure
- To evaluate the systemic pharmacokinetics of CG7870 after intravenous administration
- measure
- To monitor the immune response to CG7870
Eligibility
Eligibility (as posted)
Show eligibility record
- sex
- null
- stdAges
- CHILD
- ADULT
- OLDER_ADULT
- criteria
- null
- maximumAge
- null
- minimumAge
- null
- healthyVolunteers
- null
References
Publications (0)
Data not yet available
No reference posted for this study.